Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, Lichtenstein A.

Blood. 2010 Nov 25;116(22):4560-8. doi: 10.1182/blood-2010-05-285726.

3.

Defining the role of TORC1/2 in multiple myeloma.

Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM.

Blood. 2011 Dec 22;118(26):6860-70. doi: 10.1182/blood-2011-03-342394.

5.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

6.

Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.

Que W, Chen J, Chuang M, Jiang D.

APMIS. 2012 Mar;120(3):195-203. doi: 10.1111/j.1600-0463.2011.02836.x.

PMID:
22339676
7.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89.

8.

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.

Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, Chen J, Sun SY, Boise LH, Lonial S.

Blood. 2014 May 22;123(21):3269-76. doi: 10.1182/blood-2013-08-521914.

9.

Effective targeting of colorectal cancer cells using TORC1/2 kinase inhibitors in vitro and in vivo.

Zhang J, Jiang W, Liu W, Wu JJ, Song L, Cheng JX, Yao M, Yang LP, Yao DF.

Future Oncol. 2016 Feb;12(4):515-24. doi: 10.2217/fon.15.248.

PMID:
26776341
10.

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.

Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N.

Mol Cancer Ther. 2014 Nov;13(11):2489-500. doi: 10.1158/1535-7163.MCT-14-0147.

11.

A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.

Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.

Anticancer Drugs. 2013 Oct;24(9):889-98. doi: 10.1097/CAD.0b013e328363c64e.

PMID:
23838676
12.

mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.

Gordeev SA, Bykova TV, Zubova SG, Bystrova OA, Martynova MG, Pospelov VA, Pospelova TV.

Oncotarget. 2015 Dec 29;6(42):44905-26. doi: 10.18632/oncotarget.6457.

13.

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.

Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.

Exp Cell Res. 2009 Feb 1;315(3):485-97. doi: 10.1016/j.yexcr.2008.11.007.

PMID:
19071109
14.

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.

Xing X, Zhang L, Wen X, Wang X, Cheng X, Du H, Hu Y, Li L, Dong B, Li Z, Ji J.

Anticancer Drugs. 2014 Nov;25(10):1129-40. doi: 10.1097/CAD.0000000000000148.

15.

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.

Gera J, Lichtenstein A.

Leuk Lymphoma. 2011 Oct;52(10):1857-66. doi: 10.3109/10428194.2011.580478. Review.

PMID:
21599581
16.

The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.

Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.

Leuk Res. 2012 Jul;36(7):912-20. doi: 10.1016/j.leukres.2012.02.010.

PMID:
22560334
17.

Levels of p27 sensitize to dual PI3K/mTOR inhibition.

Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, Pellegata NS.

Mol Cancer Ther. 2011 Aug;10(8):1450-9. doi: 10.1158/1535-7163.MCT-11-0188.

18.

Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.

Huang JJ, Li ZM, Huang Y, Huang Y, Tian Y, He XX, Xiao J, Lin TY.

Invest New Drugs. 2012 Feb;30(1):223-35. doi: 10.1007/s10637-010-9558-4.

PMID:
20960030
19.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA.

Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091.

20.

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.

Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.

Cancer Res. 2006 Feb 15;66(4):2305-13.

Items per page

Supplemental Content

Support Center